Skip to main content

Table 3 Odds ratios (OR) and 95 % CI for association of serum folate concentrations with prostate cancera

From: Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness

 

Tertiles of serum folate

p trend

Folate per 10 nmol/L OR (95 % CI)

1

OR

2

OR (95 % CI)

3

OR (95 % CI)

Serum folate, nmol/L

2.9–7.3

7.4–10.9

11.0–24.0

  

Total prostate cancera

 Cases/controls

32/77

53/80

133/79

 

218/236

 Age adjusted

1.00 (ref.)

2.06 (1.15–3.67)

4.83 (2.82–8.25)

0.0001

4.81 (2.89–7.98)

 Multivariableb

1.00 (ref.)

2.82 (1.44–5.53)

5.82 (3.12–10.88)

0.0001

4.41 (2.52–7.72)

 Low-grade cancerc

     

 Cases/controls

15/77

26/80

54/79

 

95/236

 Age adjusted

1.00 (ref.)

2.07 (0.99–4.32)

4.02 (2.04–7.92)

0.0001

4..07 (2.23–7.46)

 Multivariableb

1.00 (ref.)

2.83 (1.18–6.74)

5.26 (2.34–1.84)

0.0001

3.98 (2.05–7.76)

High-grade cancerd

 Cases/controls

15/77

26/80

75/79

 

116/236

 Age adjusted

1.00 (ref.)

2.35 (1.11–4.98)

5.79 (2.95–11.36)

0.0001

4.81 (2.65–8.70)

 Multivariableb

1.00 (ref)

3.05 (1.27–7.30)

6.78 (3.06–15.03)

0.0001

4.51 (2.31–8.82)

  1. a7 cases—Gleason scores unknown
  2. bModels adjusted for age and BMI and total energy intake as continuous, education (primary or less, secondary or higher), family history of prostate cancer (no/yes), vitamin use (no/yes), alcohol intake (non-drinker, <6.4, >6.4 g/day), and smoking (non-smoker, ex-smoker, current smoker)
  3. cLow-grade cancer indicates Gleason score of <7
  4. dHigh-grade cancer indicates Gleason score of ≥7
Back to article page

Genes & Nutrition

ISSN: 1865-3499

Contact us